Lifeway Foods (LWAY) said Tuesday its board rejected Danone North America's revised acquisition offer of $27 per share because it "substantially undervalues" the company.
"The board is not, however, opposed to the sale of the company at any price," the company said in a statement, explaining the rejection last week of Danone's offer.
The supplier of kefir and fermented probiotic products said its revenue has grown for 20 consecutive quarters, with gross profit increasing 92% from 2019 to 2023.
Lifeway said it expects adjusted earnings before interest, taxes, depreciation, and amortization to more than double to between $45 million and $50 million by 2027. Danone's offer implies a "very low multiple" of 7.5x to 8.5x EBITDA, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.